← Eichor
Study identifier: NCT07219459 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Condition: Unresectable or Metastatic Hepatocellular Carcinoma · Child-Pugh A Hepatocellular Carcinoma · Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound  ·  Sponsor: CatalYm GmbH

PhasePhase 2
Planned participants104
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

This is a Phase 2b, randomized, blinded clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and Lenvatinib compared to double placebo and Lenvatinib in participants with unresectable or metastatic HCC and compensated liver function (Child-Pugh A) after failure of 1L treatment that included an anti-PD-(L)1 compound. The trial consists of 2 Parts: a non-randomized Safety-run-in part (Part 1) and the subsequent randomized part (Part 2) with 2 treatment arms (A and B). Randomization of participants into Treatment Arm A and B will continue until 40 efficacy-evaluable participants are enrolled into each Treatment Arm.

This description comes directly from the study's public registry record.

Talk to the study team

Tomáš Janík, MD  ·  +49892000664  ·  regulatory-005@catalym.com

Always discuss trial participation with your own doctor first.

Locations (14)

USC Norris Comprehensive Cancer CenterLos Angeles, California, United StatesRecruiting
Peidmont Healthcare, IncAtlanta, Georgia, United StatesRecruiting
OSF St. Francis Medical CenterPeoria, Illinois, United StatesRecruiting
Hannover Medical SchoolHanover, Lower Saxony, GermanyRecruiting
University Medical Center of Johannes Gutenberg University MainzMainz, Rhineland-Palatinate, GermanyRecruiting
Universitätsklinikum Frankfurt Johann Wolfgang Goethe- UniversitätFrankfurt, GermanyRecruiting
Polyclinic S. Orsola-MalpighiBologna, ItalyRecruiting
Asst Grande Ospedale Metropolitano NiguardaMilan, ItalyRecruiting
Ospedale S.Maria delle CrociRavenna, ItalyRecruiting
University Hospital Miguel ServetZaragoza, Aragon, SpainRecruiting
Catalan Institute of Oncology, Hospital Duran i ReynalsL'Hospitalet de Llobregat, Barcelona, SpainRecruiting
Hospital Clinic of BarcelonaBarcelona, Catalonia, SpainRecruiting

+ 2 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07219459